Stockscreener 앱 받기
47.62
0.08%
-0.04
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera draws upgrades after early-stage data for anti-inflammatory agent - MSN
Top 10 NASDAQ Stocks with Strong Growth Potential by Kalkine - Kalkine Media
Ameriprise Financial Inc. Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Q2 EPS Forecast for Kymera Therapeutics Boosted by Analyst - Defense World
Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT - MSN
Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial - Barron's
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN
BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51 - MSN
Kymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 Degrader - MSN
Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621 - MSN
JPMorgan Chase & Co. Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Upgraded to “Overweight” at Morgan Stanley - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Sees Large Volume Increase on Analyst Upgrade - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Upgraded by B. Riley to “Buy” Rating - Defense World
B. Riley Securities Upgrades Kymera Therapeutics (KYMR) - Nasdaq
Kymera Therapeutics Executives and Directors Sell Shares - TradingView
Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race - insights.citeline.com
Kymera stock draws upgrades after trial data (KYMR:NASDAQ) - Seeking Alpha
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - TradingView
Kymera STAT6 Degrader Phase 1 Data a 'Key De-Risking Event,' Morgan Stanley Says - marketscreener.com
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621 - Insider Monkey
Kymera Therapeutics (KYMR) Receives Analyst Upgrade and Price Ta - GuruFocus
Kymera Therapeutics (KYMR) Receives Analyst Upgrade and Price Target Boost | KYMR Stock News - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Upgraded to “Buy” at Bank of America - Defense World
Kymera Therapeutics (KYMR) Sees Price Target Raised by JP Morgan - GuruFocus
What 6 Analyst Ratings Have To Say About Kymera Therapeutics - Nasdaq
Stifel Adjusts Price Target on Kymera Therapeutics to $68 From $55, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics (KYMR) Sees Price Target Raised by JP Morgan | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Receives Upgraded Target Price and Positive Outlook | KYMR Stock News - GuruFocus
JPMorgan Raises Kymera Therapeutics (KYMR) Target Price Amid Positive Phase 1 Data | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Shares Boosted by Positive KT-621 Dat - GuruFocus
Where are the Opportunities in (KYMR) - news.stocktradersdaily.com
Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday - MSN
Kymera reports promising Phase 1 results for KT-621 By Investing.com - Investing.com South Africa
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - MSN
These 10 Stocks Blew Past Expectations - Insider Monkey
Kymera’s STAT6 Degrader for Inflammatory Disease Shows Early Success in Phase I - Genetic Engineering and Biotechnology News
Kymera Therapeutics (KYMR) Gains Favor with Morgan Stanley Upgrade | KYMR Stock News - GuruFocus
Kymera, with new data, takes early step toward a Dupixent-like pill - BioPharma Dive
TRUIST SECURITIES MAINTAINS BUY RATING ON KYMERA STOCK AFTER POSITIVE STUDY RESULTS - Investing.com UK
Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data (NASDAQ:KYMR) - Seeking Alpha
Citi Increases Price Target for Kymera Therapeutics (KYMR) to $6 - GuruFocus
Kymera Therapeutics (KYMR) Receives Upgrade and Price Target Boo - GuruFocus
Kymera Therapeutics (KYMR) Sees Upgrade After Promising Phase 1 Results | KYMR Stock News - GuruFocus
BofA Securities Upgrades Kymera Therapeutics to Buy From Neutral, $51 Price Target; Shares Rise - marketscreener.com
Kymera Therapeutics (KYMR) Achieves Promising Phase 1 STAT6 Resu - GuruFocus
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Stifel reiterates buy rating on Kymera stock after clinical results By Investing.com - Investing.com India
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response - Yahoo Finance
Citi maintains buy rating on Kymera stock after positive trial results - Investing.com Nigeria
Transcript : Kymera Therapeutics, Inc.Special Call - marketscreener.com
Kymera Therapeutics stock soars on positive trial results for KT-621 - Investing.com Australia
Kymera Therapeutics stock soars on positive trial results for KT-621 By Investing.com - Investing.com South Africa
Kymera jumps 16% as it prepares to release phase 1 data on inflammatory diseases asset - MSN
Kymera Therapeutics (KYMR) Soars on Positive Phase 1 Results for KT-621 - GuruFocus
Kymera Therapeutics Says KT-621 Well Tolerated in Phase 1 Trial, Showing Potential to Treat Th2 Diseases - marketscreener.com
Kymera Therapeutics, Inc. Announces Positive First-In-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, A First-In-Class, Oral Stat6 Degrader - marketscreener.com
Kymera Therapeutics Announces Positive First-In-Human Results From Phase 1 Healthy Volunteer Clinical Trial Of KT-621 - marketscreener.com
Kymera Therapeutics (KYMR) Reports Promising Results from KT-621 - GuruFocus
1.21%
1.51%
자본화:
|
볼륨(24시간):